2026 Volume: 02 Issue: 02 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-12

A QUICK REVIEW OF ADR IN NEPHRO PATIENT

Abdul Khalique Ansari, Ajay Kumar, Chandan Kumar, Vikas Chauhan*, Nakul Gupta

Department of Pharmaceutics, IIMT College of Pharmacy, Greater Noida, Uttar Pradesh, India, 201310.

Article Received: 17 March 2026
Article Revised: 07 April 2026
Published on: 27 April 2026

***Corresponding Author: Vikas Chauhan**
Department of Pharmaceutics, IIMT College of Pharmacy, Greater Noida, Uttar Pradesh, India, 201310.

DOI: https://doi-doi.org/101555/ijrpa.2814

ABSTRACT

Adverse Drug Reactions (ADRs) represent a major clinical concern in nephrology patients due to altered renal function that significantly affects drug pharmacokinetics and pharmacodynamics. Individuals suffering from chronic kidney disease (CKD) or acute kidney injury (AKI) are particularly vulnerable to drug toxicity, accumulation, and unexpected adverse effects. Impaired renal clearance leads to prolonged drug half-life, increasing the risk of dose-dependent reactions. Additionally, changes in protein binding, electrolyte imbalances, and uremic conditions further complicate drug response in these patients.

This review aims to provide a concise overview of ADRs in nephrology patients, focusing on their classification, underlying mechanisms, and associated risk factors. Special attention is given to commonly implicated drug classes such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, diuretics, and antihypertensive agents, which frequently contribute to renal complications. The clinical manifestations of ADRs, ranging from mild electrolyte disturbances to severe nephrotoxicity and systemic complications, are also discussed.

Furthermore, this review highlights key strategies for prevention and management, including dose adjustment based on glomerular filtration rate (GFR), therapeutic drug monitoring, and avoidance of nephrotoxic medications. The role of pharmacovigilance and emerging technologies such as artificial intelligence in predicting and preventing ADRs is also emphasized. Understanding and early identification of ADRs in nephrology patients are essential for optimizing therapeutic outcomes, minimizing complications, and improving overall patient safety in clinical practice.

KEYWORDS: Adverse Drug Reactions, Chronic Kidney Disease, Nephrotoxicity, Pharmacovigilance, Therapeutic Drug Monitoring.

INTRODUCTION

Adverse Drug Reactions (ADRs) are defined by the World Health Organization (WHO) as any noxious, unintended, and undesired effect of a drug that occurs at normal therapeutic doses used for prophylaxis, diagnosis, or treatment. ADRs represent a significant cause of morbidity and mortality worldwide and are a major concern in clinical practice. Among various patient populations, individuals with renal impairment, particularly those suffering from chronic kidney disease (CKD) or acute kidney injury (AKI), are at a substantially higher risk of developing ADRs.

The kidneys play a crucial role in the elimination of many drugs and their metabolites. In nephrology patients, impaired renal function leads to reduced drug clearance, resulting in drug accumulation and prolonged exposure. This alteration in pharmacokinetics is often accompanied by changes in pharmacodynamics, making patients more sensitive to drug effects. Additionally, uremic toxins, altered protein binding, and fluid and electrolyte imbalances further complicate drug therapy in these individuals.

The global burden of CKD is steadily increasing, with millions of patients requiring long-term pharmacotherapy for the management of comorbid conditions such as hypertension, diabetes, and cardiovascular diseases. This often results in polypharmacy, which significantly raises the risk of drug-drug interactions and ADRs. Furthermore, elderly patients, who constitute a large proportion of nephrology cases, are particularly vulnerable due to age-related physiological changes.

Given these challenges, understanding the nature, causes, and risk factors of ADRs in nephrology patients is essential for safe and effective drug therapy. Early identification, appropriate dose adjustment based on renal function, and careful monitoring can help reduce the incidence of ADRs. This review aims to provide a comprehensive overview of ADRs in nephrology patients, highlighting key aspects necessary for improving clinical outcomes and patient safety.

Classification Of Adverse Drug Reaction (ADRs)

Adverse Drug Reactions (ADRs) are broadly classified based on their mechanism, predictability, and time of occurrence. The most commonly used classification system categorizes ADRs into Types A, B, C, D, and E.

Type A (Augmented) reactions are dose-dependent and predictable, resulting from the known pharmacological actions of the drug. These are the most common type of ADRs and are often observed in nephrology patients due to drug accumulation caused by impaired renal clearance. For example, excessive anticoagulation with warfarin or hypoglycemia with antidiabetic drugs can occur when drug doses are not appropriately adjusted.

Type B (Bizarre) reactions are unpredictable, not dose-dependent, and unrelated to the pharmacological action of the drug. These reactions are often immune-mediated or idiosyncratic in nature. Examples include allergic reactions such as rash, anaphylaxis, or drug-induced lupus.

Type C (Chronic) reactions are associated with long-term therapy and cumulative dose. These reactions develop over time and may persist even after discontinuation of the drug. In nephrology patients, prolonged use of certain analgesics may lead to chronic kidney damage.

Type D (Delayed) reactions become apparent after some time, even after the drug has been discontinued. These include carcinogenic or teratogenic effects of certain medications.

Type E (End-of-use) reactions occur upon sudden withdrawal of a drug. These reactions are commonly seen with drugs that cause physiological dependence, such as corticosteroids or antihypertensive medications.

Mechanism Of Adverse Drug Reaction In Nephrology Patient.

The occurrence of Adverse Drug Reactions (ADRs) in nephrology patients is primarily influenced by alterations in pharmacokinetics and pharmacodynamics due to impaired renal function. The kidneys play a vital role in the elimination of drugs and their metabolites; therefore, any decline in renal function significantly affects drug handling in the body, leading to an increased risk of toxicity.

One of the major mechanisms contributing to ADRs is reduced renal clearance. In patients with chronic kidney disease (CKD) or acute kidney injury (AKI), the glomerular filtration

rate (GFR) is decreased, resulting in accumulation of drugs and their active metabolites. This prolonged exposure increases the likelihood of dose-dependent adverse effects.

Another important mechanism is altered protein binding. In renal impairment, the accumulation of uremic toxins can displace drugs from plasma proteins, leading to an increased free (active) fraction of the drug in circulation. This enhances drug activity and toxicity even when total drug concentration appears normal.

Electrolyte imbalance is also a key contributing factor. Many drugs influence electrolyte levels, and in renal patients, disturbances such as hyperkalemia or hyponatremia can be exacerbated, leading to serious complications like cardiac arrhythmias.

Additionally, changes in drug metabolism may occur due to impaired renal function affecting hepatic enzyme activity. The interaction between kidney and liver functions can alter the overall pharmacokinetic profile of drugs.

Polypharmacy, which is common in nephrology patients, further increases the risk of drug-drug interactions. These interactions can modify drug absorption, distribution, metabolism, or excretion, thereby contributing to ADRs.

Overall, the mechanisms of ADRs in nephrology patients are multifactorial and complex, requiring careful consideration of renal function, drug properties, and patient-specific factors to ensure safe and effective therapy.

Risk Factor For ADRs In Nephrology Patients

Nephrology patients are particularly vulnerable to Adverse Drug Reactions (ADRs) due to the presence of multiple predisposing risk factors. These factors not only increase the likelihood of ADR occurrence but also contribute to their severity and clinical outcomes.

One of the most significant risk factors is impaired renal function itself. As kidney function declines, the elimination of drugs and their metabolites is reduced, leading to accumulation and increased toxicity. The severity of chronic kidney disease (CKD) or acute kidney injury (AKI) directly correlates with the risk of ADRs.

Age is another important determinant. Elderly patients constitute a large proportion of nephrology cases and are at higher risk due to age-related physiological changes, including

reduced renal function, altered drug metabolism, and increased sensitivity to medications. These changes make them more susceptible to both predictable and unpredictable ADRs.

Polypharmacy, defined as the use of multiple medications simultaneously, is highly prevalent among nephrology patients. The presence of comorbid conditions such as hypertension, diabetes, and cardiovascular diseases necessitates complex drug regimens, increasing the risk of drug-drug interactions and cumulative toxicity.

Comorbidities further complicate drug therapy. Conditions like diabetes mellitus and liver disease can alter pharmacokinetics and pharmacodynamics, thereby enhancing the risk of adverse effects. Additionally, electrolyte imbalances and fluid disturbances commonly seen in renal patients can exacerbate drug toxicity.

Genetic factors also play a role in individual susceptibility to ADRs. Variations in genes encoding drug-metabolizing enzymes and transporters can influence drug response and toxicity.

Other contributing factors include inappropriate dosing, lack of dose adjustment according to glomerular filtration rate (GFR), and inadequate monitoring of drug therapy. Poor patient adherence and lack of awareness about medication use may also increase the risk of ADRs.
Understanding these risk factors is essential for clinicians to identify high-risk patients, implement preventive strategies, and ensure safer pharmacotherapy in nephrology practice.

Common Drugs Causing ADRs In Nephrology Patients.

Nephrology patients are frequently exposed to a wide range of medications due to associated comorbidities, making them highly susceptible to drug-induced adverse effects. Certain classes of drugs are particularly known for causing ADRs in patients with impaired renal function.

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common causes of drug-induced nephrotoxicity. These drugs inhibit prostaglandin synthesis, leading to reduced renal blood flow and potential acute kidney injury, especially in patients with pre-existing renal impairment.

Antibiotics, particularly aminoglycosides such as gentamicin and glycopeptides like vancomycin, are well known for their nephrotoxic potential. These drugs can cause tubular damage and lead to both acute and chronic kidney injury if not properly monitored.

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely used in nephrology patients for hypertension and proteinuria management. However, they may lead to hyperkalemia and a decline in glomerular filtration rate, especially in patients with advanced kidney disease.

Diuretics, commonly prescribed for fluid management, can cause significant electrolyte imbalances such as hypokalemia, hyponatremia, and dehydration. Loop diuretics like furosemide are frequently associated with such adverse effects.

Radiographic contrast agents used in diagnostic imaging procedures can lead to contrast-induced nephropathy, particularly in patients with pre-existing renal dysfunction.
Other drugs such as antidiabetics (e.g., metformin), anticoagulants, and certain antivirals also require careful dose adjustment in renal patients to prevent toxicity.

TABLE 1: Common Drugs Causing ADRs In Nephrology Patient.

Drug Class	Example	Common ADR	Mechanism
NSAIDs	Ibuprofen	Nephrotoxicity	Reduced Renal Blood Flow
Antibiotics	Gentamicin	Nephrotoxicity, Ototoxicity	Tubular Damage
ACE Inhibitors	Enalapril	Hyperkalemia	Decreased Aldestrone
Diuretics	Furosemide	Electrolyte Imbalance	Excess Fluid Loss
Contrast Agents	Iohexol	AKI	Direct Renal Toxicity
Antidiabetics	Metformin	Lactic Acidosis	Drug Accumulation

Clinical Manifestations Of ADRs In Nephrology Patients

Adverse Drug Reactions (ADRs) in nephrology patients can present with a wide spectrum of clinical manifestations, ranging from mild and reversible symptoms to severe and life-threatening complications. The presentation often depends on the type of drug involved, the degree of renal impairment, and patient-specific factors.

One of the most common manifestations is acute kidney injury (AKI), which may occur due to nephrotoxic drugs such as NSAIDs, antibiotics, and contrast agents. Patients may present with reduced urine output, elevated serum creatinine levels, and fluid retention. If not recognized early, this condition can progress to severe renal failure.

Electrolyte imbalances are also frequently observed in nephrology patients experiencing ADRs. Hyperkalemia is particularly dangerous and may result from drugs such as ACE inhibitors, potassium-sparing diuretics, or certain antibiotics. Symptoms may include muscle weakness, fatigue, and life-threatening cardiac arrhythmias. Similarly, hyponatremia and hypokalemia may occur due to excessive diuretic use.

Gastrointestinal disturbances such as nausea, vomiting, and diarrhea are common ADRs associated with many medications. These symptoms can further complicate the clinical condition by causing dehydration and worsening renal function.

Cardiovascular effects, including hypotension and arrhythmias, may occur due to drug-induced fluid imbalance or electrolyte disturbances. For example, excessive use of antihypertensive agents may lead to dangerously low blood pressure, reducing renal perfusion.

Hypersensitivity reactions such as skin rash, itching, and in severe cases, anaphylaxis may also occur, particularly with antibiotics and other immunogenic drugs. These reactions are generally unpredictable and require immediate medical attention.

Neurological symptoms, including dizziness, confusion, and altered mental status, may result from drug accumulation, especially in elderly patients or those with severe renal impairment. Overall, early recognition of these clinical manifestations is crucial for timely intervention, prevention of complications, and improvement of patient outcomes in nephrology practice.

Preventation And Management Of ADRs Of Nephrology Patients

The prevention and management of Adverse Drug Reactions (ADRs) in nephrology patients are critical components of safe and effective pharmacotherapy. Due to the high risk associated with impaired renal function, a proactive and individualized approach is essential to minimize drug-related complications.

One of the most important strategies is dose adjustment based on renal function. Parameters such as glomerular filtration rate (GFR) or creatinine clearance should be routinely assessed to guide appropriate dosing. Many drugs require dose reduction or increased dosing intervals in patients with renal impairment to prevent accumulation and toxicity.

Therapeutic drug monitoring (TDM) plays a vital role in optimizing drug therapy, especially for medications with a narrow therapeutic index such as aminoglycosides and vancomycin. Regular monitoring of drug plasma concentrations helps ensure efficacy while minimizing toxicity.

Avoidance of nephrotoxic drugs whenever possible is another key preventive measure. Alternative medications with a safer renal profile should be considered, particularly in patients with advanced kidney disease. If the use of such drugs is unavoidable, close monitoring is required.

Maintaining adequate hydration is essential, especially when administering drugs that may affect renal function or during procedures involving contrast agents. Proper hydration helps in maintaining renal perfusion and reducing the risk of drug-induced kidney injury.

Regular monitoring of renal function tests, electrolyte levels, and clinical parameters is necessary for early detection of ADRs. Prompt identification allows timely intervention, such as dose modification or drug discontinuation.

Patient education is also an important aspect of ADR prevention. Patients should be informed about their medications, possible side effects, and the importance of adherence to prescribed doses. They should also be encouraged to report any unusual symptoms immediately.

Overall, a multidisciplinary approach involving physicians, pharmacists, and healthcare professionals is essential for the effective prevention and management of ADRs in nephrology patients.

TABLE 2: Strategies For Prevention And Management Of ADRs.

Strategy	**Description**
Dose Adjustment	Modify Dose Based On GFR/Creatinine Clearance
Therapeutic Drug Monitoring	Regular Measurement Of Drug Levels
Avoid Nephrotoxic Drugs	Use Safer Alternatives When Possible
Hydration	Maintain Adequate Fluid Balance
Monitoring	Regular Renal Function And Electrolyte Checks
Patient Education	Awareness About Drug Use And Side Effects

Recent Advances In ADR Monitoring And Management

Recent advances in healthcare technology have significantly improved the detection, monitoring, and prevention of Adverse Drug Reactions (ADRs), particularly in high-risk

populations such as nephrology patients. These innovations aim to enhance patient safety, optimize drug therapy, and support clinical decision-making.

One of the major advancements is the development of pharmacovigilance systems. These systems collect, analyze, and monitor data related to ADRs from various sources, including hospitals and clinical trials. They help in early detection of drug-related risks and contribute to safer medication practices. National and international reporting systems have strengthened drug safety surveillance.

Artificial intelligence (AI) and machine learning (ML) are increasingly being integrated into healthcare to predict and prevent ADRs. These technologies analyze large datasets, including electronic health records (EHRs), to identify patterns and risk factors associated with ADRs. In nephrology patients, AI can assist in predicting drug toxicity based on renal function and patient-specific variables.

Clinical decision support systems (CDSS) are also widely used to assist healthcare professionals in prescribing safe medications. These systems provide alerts for potential drug-drug interactions, incorrect dosing, and contraindications, especially in patients with impaired renal function.

Another important development is the use of electronic prescribing (e-prescribing) systems, which reduce medication errors by ensuring accurate dosing and proper documentation. These systems often include built-in alerts for dose adjustments based on kidney function.
The concept of personalized medicine is gaining importance, where drug therapy is tailored according to individual patient characteristics, including genetic factors, disease condition, and renal function. This approach helps in minimizing ADRs and improving therapeutic outcomes.

Overall, these technological advancements are transforming the management of ADRs in nephrology patients, enabling more precise, efficient, and safer drug therapy.

Future Perspectives

The future of managing Adverse Drug Reactions (ADRs) in nephrology patients lies in the advancement of personalized and precision medicine. With the integration of genomics, proteomics, and advanced diagnostic tools, it is becoming increasingly possible to predict individual patient responses to drugs and tailor therapy accordingly.

The growing use of artificial intelligence (AI) and machine learning (ML) is expected to further enhance ADR prediction and prevention. These technologies can analyze large datasets to identify risk patterns and support clinicians in making informed decisions regarding drug selection and dosing.

Development of more renal-friendly drugs and safer therapeutic alternatives is another promising area. Pharmaceutical research is increasingly focusing on designing drugs with minimal nephrotoxic effects and improved safety profiles for patients with kidney disease.

Strengthening pharmacovigilance systems and encouraging ADR reporting will also play a crucial role in improving drug safety. Increased awareness among healthcare professionals and patients can lead to early detection and better management of ADRs.

Furthermore, global collaboration and inclusion of nephrology patients in clinical trials will help generate more robust data, ultimately leading to safer and more effective treatment strategies. These advancements will significantly improve patient outcomes and reduce the burden of ADRs in nephrology practice.

CONCLUSION

Adverse Drug Reactions (ADRs) represent a significant challenge in the management of nephrology patients due to altered renal function and the complexity of drug therapy. Patients with chronic kidney disease (CKD) and acute kidney injury (AKI) are particularly vulnerable to drug toxicity as a result of impaired drug clearance, altered pharmacokinetics, and increased sensitivity to medications.

This review highlights that multiple factors, including polypharmacy, comorbid conditions, age, and inappropriate dosing, contribute to the high incidence of ADRs in this population. Commonly used drugs such as NSAIDs, antibiotics, diuretics, and antihypertensive agents are frequently associated with adverse effects, emphasizing the need for cautious prescribing practices.

Early identification of ADRs through proper clinical monitoring and awareness of symptoms is essential to prevent serious complications. Strategies such as dose adjustment based on renal function, therapeutic drug monitoring, avoidance of nephrotoxic drugs, and patient education play a vital role in minimizing risks.

Recent advancements, including pharmacovigilance systems, artificial intelligence, and clinical decision support tools, have improved the ability to predict, detect, and manage ADRs effectively. However, challenges such as limited clinical data, resource constraints, and variability in patient response still persist.

In conclusion, a multidisciplinary and patient-centered approach is necessary to optimize drug therapy and ensure safety in nephrology patients. Continuous monitoring, rational drug use, and adoption of modern technologies can significantly reduce the burden of ADRs and improve overall clinical outcomes.

Furthermore, strengthening healthcare systems through better training of healthcare professionals and increasing awareness among patients can greatly enhance ADR prevention. Implementation of standardized treatment guidelines and regular audits of prescribing practices can help in minimizing medication errors. Encouraging active reporting of ADRs will contribute to improved pharmacovigilance databases. Ultimately, integrating clinical expertise with technological advancements will play a key role in achieving safer and more effective therapeutic outcomes in nephrology patients.

REFRENCES

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259.
2. World Health Organization. International drug monitoring: the role of national centres. WHO; 1972.
3. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital. BMJ. 2004;329:15–19.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200–1205.
5. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients. PLoS One. 2009;4(2):e4439.
6. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure. 5th ed. Philadelphia: ACP Press; 2007.
7. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1–138.
8. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function. N Engl J Med. 2006;354:2473–2483.
9. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in renal impairment. Clin Pharmacol Ther. 2011;90(2):324–334.

10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating ADR probability. Clin Pharmacol Ther. 1981;30(2):239–245.
11. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of CKD. Kidney Int. 2005;67:2089–2100.
12. Perazella MA. Drug-induced nephropathy. Am J Med. 2000;109(4):307–314.
13. Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care. 2005;11:555–565.
14. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network report. Crit Care. 2007;11:R31.
15. Fanos V, Cataldi L. Renal transport of antibiotics. J Chemother. 2001;13(2):115–121.
16. Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure. Am J Kidney Dis. 1994;24(1):1–66.
17. Perazella MA, Moeckel GW. Nephrotoxicity from drugs. Clin J Am Soc Nephrol. 2010;5(12):226–239.
18. Kooman JP, van der Sande FM, Leunissen KM. Kidney disease and drug handling. Kidney Int. 2007;72:131–135.
19. Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 2nd ed. ASHP; 2010.
20. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly. Br J Clin Pharmacol. 2004;57:121–126.
21. Turnheim K. Drug therapy in elderly patients. Exp Gerontol. 2004;39:1731–1738.
22. Hilmer SN, Gnjidic D. Polypharmacy in elderly. Clin Pharmacol Ther. 2009;85:86–88.
23. Perazella MA. Pharmacology behind nephrotoxicity. Clin J Am Soc Nephrol. 2018;13:1897–1908.
24. Muriithi AK, Leung N. Drug-induced kidney disease. Clin Med. 2013;13(4):345–350.
25. Gupta SK, Nayak RP. Adverse drug reactions in India. Indian J Pharmacol. 2011;43(1):1–3.
26. Sharma VK, Sethuraman G, Kumar B. Cutaneous ADRs. Indian J Dermatol Venereol Leprol. 2001;67:155–158.
27. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events. JAMA. 1995;274:29–34.
28. Rawlins MD, Thompson JW. Mechanisms of ADRs. Textbook of Adverse Drug Reactions. 1977.
29. Whelton A. Nephrotoxicity of NSAIDs. Am J Med. 1999;106:13–24.
30. Kellum JA, Lameire N. Diagnosis of AKI. Kidney Int Suppl. 2013;3:19–36.